The Therapeutic Effects of Dodecaborate Containing Boronophenylalanine for Boron Neutron Capture Therapy in a Rat Brain Tumor Model.
boron neutron capture therapy (BNCT)
boronophenylalanine–amide alkyl dodecaborate (BADB)
malignant glioma
survival prolongation
Journal
Biology
ISSN: 2079-7737
Titre abrégé: Biology (Basel)
Pays: Switzerland
ID NLM: 101587988
Informations de publication
Date de publication:
01 Dec 2020
01 Dec 2020
Historique:
received:
18
10
2020
revised:
26
11
2020
accepted:
29
11
2020
entrez:
4
12
2020
pubmed:
5
12
2020
medline:
5
12
2020
Statut:
epublish
Résumé
The development of effective boron compounds is a major area of research in the study of boron neutron capture therapy (BNCT). We created a novel boron compound, boronophenylalanine-amide alkyl dodecaborate (BADB), for application in BNCT and focused on elucidating how it affected a rat brain tumor model. The boron concentration of F98 rat glioma cells following exposure to boronophenylalanine (BPA) (which is currently being utilized clinically) and BADB was evaluated, and the biodistributions in F98 glioma-bearing rats were assessed. In neutron irradiation studies, the in vitro cytotoxicity of each boron compound and the in vivo corresponding therapeutic effect were evaluated in terms of survival time. The survival fractions of the groups irradiated with BPA and BADB were not significantly different. BADB administered for 6 h after the termination of convection-enhanced delivery ensured the highest boron concentration in the tumor (45.8 μg B/g). The median survival time in the BADB in combination with BPA group showed a more significant prolongation of survival than that of the BPA group. BADB is a novel boron compound for BNCT that triggers a prolonged survival effect in patients receiving BNCT.
Sections du résumé
BACKGROUND
BACKGROUND
The development of effective boron compounds is a major area of research in the study of boron neutron capture therapy (BNCT). We created a novel boron compound, boronophenylalanine-amide alkyl dodecaborate (BADB), for application in BNCT and focused on elucidating how it affected a rat brain tumor model.
METHODS
METHODS
The boron concentration of F98 rat glioma cells following exposure to boronophenylalanine (BPA) (which is currently being utilized clinically) and BADB was evaluated, and the biodistributions in F98 glioma-bearing rats were assessed. In neutron irradiation studies, the in vitro cytotoxicity of each boron compound and the in vivo corresponding therapeutic effect were evaluated in terms of survival time.
RESULTS
RESULTS
The survival fractions of the groups irradiated with BPA and BADB were not significantly different. BADB administered for 6 h after the termination of convection-enhanced delivery ensured the highest boron concentration in the tumor (45.8 μg B/g). The median survival time in the BADB in combination with BPA group showed a more significant prolongation of survival than that of the BPA group.
CONCLUSION
CONCLUSIONS
BADB is a novel boron compound for BNCT that triggers a prolonged survival effect in patients receiving BNCT.
Identifiants
pubmed: 33271972
pii: biology9120437
doi: 10.3390/biology9120437
pmc: PMC7759915
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Neurotherapeutics. 2017 Apr;14(2):358-371
pubmed: 28299724
Int J Mol Sci. 2018 Jun 01;19(6):
pubmed: 29865203
Int J Radiat Oncol Biol Phys. 2012 Jan 1;82(1):e67-75
pubmed: 21300462
Cancer Lett. 2016 Jan 1;370(1):27-32
pubmed: 26455769
Radiat Oncol. 2012 Aug 29;7:146
pubmed: 22929110
J Neurooncol. 2011 Jun;103(2):175-85
pubmed: 20848301
Radiat Environ Biophys. 2019 Mar;58(1):59-67
pubmed: 30474719
Int J Radiat Oncol Biol Phys. 1994 Oct 15;30(3):643-52
pubmed: 7928496
Proc Natl Acad Sci U S A. 2013 Apr 16;110(16):6512-7
pubmed: 23536304
Bioconjug Chem. 2013 Jan 16;24(1):124-32
pubmed: 23214414
J Control Release. 2017 May 28;254:1-9
pubmed: 28336377
J Med Invest. 2014;61(3-4):254-63
pubmed: 25264042
J Radiat Res. 2018 Mar 1;59(2):122-128
pubmed: 29315429
Anticancer Agents Med Chem. 2006 Mar;6(2):111-25
pubmed: 16529535
J Neurooncol. 2009 Jan;91(2):199-206
pubmed: 18813875
Pigment Cell Res. 1989 Jul-Aug;2(4):226-34
pubmed: 2678078
Biomaterials. 2014 Mar;35(10):3396-405
pubmed: 24452095
Cancer Res. 1986 Dec;46(12 Pt 1):6387-92
pubmed: 2946403
J Radiat Res. 2014 Jan 1;55(1):146-53
pubmed: 23955053
Int J Radiat Biol. 2015 Jan;91(1):81-9
pubmed: 25004948
Org Biomol Chem. 2015 Jul 7;13(25):6927-30
pubmed: 26022725
Biomaterials. 2012 May;33(13):3568-77
pubmed: 22326646
J Neurooncol. 2003 Nov;65(2):159-65
pubmed: 14686736
Mol Cancer Ther. 2008 Jul;7(7):1763-71
pubmed: 18644988
Cancer Commun (Lond). 2018 Jun 19;38(1):35
pubmed: 29914561
Org Biomol Chem. 2019 Jun 5;17(22):5496-5499
pubmed: 30976763
Br J Cancer. 1997;75(5):660-5
pubmed: 9043021
Bioconjug Chem. 1991 Jul-Aug;2(4):242-53
pubmed: 1772906
Neurosurgery. 2011 May;68(5):1380-7; discussion 1387
pubmed: 21273928
Radiother Oncol. 1994 Sep;32(3):249-55
pubmed: 7816943
J Neurooncol. 2009 Sep;94(3):299-312
pubmed: 19381449
Front Pharmacol. 2018 Jan 26;9:27
pubmed: 29434548
J Neurosurg. 2013 Oct;119(4):837-44
pubmed: 23808536
Chem Rev. 1998 Jun 18;98(4):1515-1562
pubmed: 11848941
Radiat Oncol. 2017 Jan 23;12(1):26
pubmed: 28114947
Radiat Prot Dosimetry. 2005;116(1-4 Pt 2):109-12
pubmed: 16604608
J Control Release. 2004 Aug 11;98(2):195-207
pubmed: 15262412
J Radiat Res. 2009 Jan;50(1):51-60
pubmed: 18957828
J Org Chem. 1997 Jun 27;62(13):4476-4478
pubmed: 11671777
Clin Cancer Res. 2002 Aug;8(8):2675-83
pubmed: 12171900
Radiat Res. 2000 Feb;153(2):173-80
pubmed: 10629616